Upfront Treatment With Chemotherapy and Bevacizumab in Advanced Ovarian Cancer

Nada Hassan Salah

Status and phase: Unknown; Phase 2

Conditions: Advanced Ovarian Cancer

Treatments: Drug: Bevacizumab

Study type: Interventional

Funder types: Other

Identifiers

NCT03611179

bevacizumab in ovarian cancer

Details and patient eligibility

About

Our study aims at assessment of response, survival and toxicity of frontline treatment with chemotherapy and Bevacizumab in patients having advanced epithelial ovarian cancer.

Full description

Ovarian cancer is the most lethal gynecologic malignancy and is the fifth most common cause of cancer death in women .The majority of women with ovarian cancer are diagnosed with advanced-stage disease; only 15% of all cases are diagnosed with local disease. Risk factors for ovarian cancer include family history, nulliparity, lack of breast feeding, and infertility .

The GOG-0218 trial demonstrated that the use of bevacizumab in the front-line and maintenance setting improved progression free survival by 3.8 months when compared with conventional every-3-weeks carboplatin and paclitaxel.

The ICON-7 trial also aimed to compare the progression free survival and Overall survival in women who receive bevacizumab with carboplatin/paclitaxel and women receiving carboplatin/paclitaxel alone The final results of ICON7 were announced in 2013. Overall, the results showed no difference in overall survival between those in the group receiving bevacizumab han those in the group receiving no bevacizumab. However, for high-risk patients, who were most likely to have early disease progression, the results were positive and showed an improvement in overall survival of 4.8 months in the group who received bevacizumab.

Not only has the best route been intensely debated but the optimal timing of therapy has been and is currently being studied. Chemotherapy is usually given either only after primary debulking surgery or as both neoadjuvant chemotherapy before and after interval debulking surgery. recent trials have tried to determine which treatment timing is associated with better outcomes .

The aim of the study will be assessment of response, survival and toxicity of frontline treatment with chemotherapy and Bevacizumab in patients having advanced epithelial ovarian cancer.

Enrollment: 40 estimated patients

Sex: Female

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Female patients diagnosed with advanced ovarian cancer by biopsy
• Age more than 18 years old
• Routine labs are within normal values ( CBC, renal function tests , liver function tests )
• Performance score 0-2
• FIGO stage II-IV
• Not having any contraindication to bevacizumab as : uncontrolled hypertension , bleeding tendency , ischaemic events
• Chemotherapy naïve.
• Informed consent

Exclusion criteria

• patients previously received chemotherapy or radiotherapy to any part of the abdomen or pelvis
• patients with uncontrolled infection
• patients with clinically significant cardiovascular disease
• patients with active bleeding or conditions associated with high risk of bleeding
• patients with history of CNS disease

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

40 participants in 1 patient group

advanced ovarian cancer cases

Experimental group

Description:

patients with advanced ovarian cancer will receive Bevacizumab 15 mg/kg every 21 days with chemotherapy (Paclitaxel 175 mg/m2 \& Carboplatin AUC 5 every 21 days)

Treatment:

Drug: Bevacizumab